Pharmaceutical giant Johnson & Johnson ( JNJ +0.38% ) has performed well this year. The company's shares are up by 45% since January.

However, many investors, including institutional ones, still believe the healthcare leader has more upside ahead and have recently increased their stakes in the company. For instance, Bank of Nova Scotia , one of the largest banks in Canada, recently added thousands more shares of Johnson & Johnson, thereby increasing its stake in the company by 29%. Vanguard Group, a leading investment management firm, also bought more of Johnson & Johnson's stock.

With these and several other institutional investors buying shares of the healthcare specialist, should you follow their lead?

Johnson & Johnson is showing resilience

While 2025 has been a strong ye

See Full Page